3 results match your criteria: "Dr. Cipto Mangunkusumo National Public Hospital[Affiliation]"
The association of apolipoprotein in the risk of ST-elevation myocardial infarction in patients with documented coronary artery disease.
Int J Cardiol Cardiovasc Risk Prev
September 2023
Clinical Pathology Department, Faculty of Medicine Universitas Indonesia, Dr. Cipto Mangunkusumo National Public Hospital, Central Jakarta, Indonesia.
Article Synopsis
- Cardiovascular disease (CVD), particularly acute coronary syndrome (ACS), is the leading cause of death globally, with risk factors ranging from non-modifiable, like age and family history, to modifiable ones such as dyslipidemia and hypertension.
- A study involving 62 STEMI patients and 20 non-ACS CAD patients investigated the correlation between apolipoproteins and ACS, revealing distinct differences in apoA1 levels and the apoB/apoA1 ratio between the two groups.
- The findings indicate that hypertension and apoA1 are significant risk factors for STEMI, suggesting that monitoring these can help identify individuals at risk for myocardial infarction.
The role of clopidogrel resistance-related genetic and epigenetic factors in major adverse cardiovascular events among patients with acute coronary syndrome after percutaneous coronary intervention.
Front Cardiovasc Med
February 2023
Universitas Indonesia Hospital, Universitas Indonesia, Depok, Indonesia.
Despite patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel therapy, some patients still experience major adverse cardiovascular events (MACEs). Clopidogrel resistance, which may be regulated by genetic and epigenetic factors, may play a role in MACEs. This study aimed to determine the association between genetic ( and polymorphisms) and epigenetic (DNA methylation of and and miRNA-26a expression) factors and their effects on MACEs among post-PCI patients.
View Article and Find Full Text PDFIncrease in the risk of clopidogrel resistance and consequent TIMI flow impairment by DNA hypomethylation of CYP2C19 gene in STEMI patients undergoing primary percutaneous coronary intervention (PPCI).
Pharmacol Res Perspect
April 2021
Cardiology and Vascular Medicine Department, Faculty of Medicine Universitas Indonesia, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia.
Clopidogrel resistance is an important risk factor of ischemic event recurrence after optimal antiplatelet therapy. This study aims to investigate the role of CYP2C19 gene DNA methylation as one of the epigenetic factors for the risk of clopidogrel resistance in STEMI patients undergoing PPCI. ST-segment elevation myocardial infarction (STEMI) patients undergoing PPCI were pretreated with clopidogrel, and their platelet function was measured using VerifyNow™ assay.
View Article and Find Full Text PDF